GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Total Stockholders Equity

Kyverna Therapeutics (Kyverna Therapeutics) Total Stockholders Equity : $360.99 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Total Stockholders Equity?

Kyverna Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $360.99 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Kyverna Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $8.37. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Kyverna Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.03.

Kyverna Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Kyverna Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Total Stockholders Equity Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Stockholders Equity
-46.25 -74.00 -131.40

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial -74.00 - -111.81 -131.40 360.99

Kyverna Therapeutics  (NAS:KYTX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Kyverna Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(360.991-0)/43.1152
=8.37

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Kyverna Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.718 + 7.128) / 360.991
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Total Stockholders Equity
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Website
https://www.kyvernatx.com
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024